A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer
NCT #
NCT05256290
Condition(s)
GBM (Glioblastoma), Lung Cancer (NSCLC)
Molecular Target(s)
EGFR
Drug Classification(s)
Small Molecule (Targeted)
Agents(s)
BDTX-1535
Phase(s)
I
Mechanism of Action
BDTX-1535 selectively targets, irreversibly binds to, and inhibits the activity of various EGFR alterations and mutations. This prevents EGFR-mediated signaling in susceptible tumor cells. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells.
Purpose
- How much of BDTX-1535 can be given with an acceptable level of side effects alone and in combination with temozolomide
- The effects of BDTX-1535 (good and bad) alone and in combination with temozolomide
- How much of BDTX-1535 is absorbed into the blood and how fast it is removed
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.